Medivation, Inc. (NASDAQ:MDVN)

CAPS Rating: 3 out of 5

A biopharmaceutical company engaged in the acquisition, research and development of promising medical technologies.


Player Avatar KurtEng (31.24) Submitted: 8/17/2011 4:22:41 PM : Underperform Start Price: $7.84 MDVN Score: -1,134.49

I would never put my own money into this stock. They will have to grow like crazy to justify the current price and so far they haven't generated any positive cash flow. The downside seems huge.

Member Avatar TSIF (99.96) Submitted: 11/3/2011 11:32:02 AM
Recs: 0

You can't value biopharms in the same way you do other company's. It's all about the pipeline, drug study's, chance of approval by the FDA, then notice from the FDA and if approved, whether reality meets expectations.

Track DNDN for the last three years for an example...

Biopharms have nothing to do with cash flow.

Study some of zzlangerhan 's calls and pitches if you are interested in the volitile world of valuation that has no technical correlations. He "specializes in biopharms" but no one can call these reliably. Good luck.

Featured Broker Partners